Published in final edited form as:

Org Lett. 2009 February 19; 11(4): 943–946. doi:10.1021/ol802930q.

Rapid, General Access to Chiral β -Fluoroamines and β , β -Difluoroamines via Organocatalysis

Olugbeminiyi O. Fadeyi and Craig W. Lindsley*

Departments of Chemistry and Pharmacology, Vanderbilt University, Nashville, Tennessee 37232.

Abstract

A rapid, general route to enantiopure β -fluoroamines and β , β -difluoroamines has been developed employing organocatalysis in both a two-pot and a one-pot procedure. Both chemical yields (64–82%) and enantioselectivity (94–98% ee) were excellent and represent a significant improvement in the art of preparing chemically diverse β -fluoroamines from readily available precursors.

The incorporation of β -fluoroamines into drug candidates has increased dramatically in the past five years, with >150 fluorinated drug candidates in Phase II and Phase III clinical trials.¹ The role of the β -fluorine atom is diverse and has been shown to enhance binding interactions, improve metabolic stability, increase CNS penetration and eliminate ancillary ion channel activity by attenuating amine basicity (pKa).^{1–5} The inductive effects of a β -fluorine atom are pronounced, lowering the pKa of a linear aliphatic amine (pKa ~10.7) to pKa ~9.0, with a single β -fluorine to pKa ~7.3 with β , β -difluoro substitution. These effects are general and additive, with a β -CF₃ moiety lowering the pKa to ~5.7.^{1–6}

Despite the importance of the β -fluoroamine moiety, there are few synthetic methods in the literature for their preparation.^{1–7} Two common methods, the ring opening of aziridines with nucleophilic fluoride sources⁸ and the hydrofluorination of olefins,⁹ deliver β -fluoroamines, but lack generality/substrate scope, require starting materials that are not readily available or, in the latter case, do not provide access to enantiopure β -fluoroamines. The route most utilized involves the treatment of ketones or secondary alcohols with DAST, (diethylamino)sulfur trifluoride, to provide β , β -difluoroamine and β -fluoroamines (with inversion of stereochemistry), respectively.^{1–10} However, this methodology requires the synthesis of enantiopure secondary alcohols and then suffers from the formation of rearranged and dehydrated products, which, in many published cases, greatly diminished yields of the desired β -fluoroamines.¹⁰ In this Letter, we describe general and high-yielding protocols to deliver enantiopure β -fluoroamines and β , β -difluoroamines employing organocatalysis and readily available starting materials.

We were attracted to the classical MacMillan work¹¹ where organocatalysis was employed to deliver enantioselective (91–99% ee) α -fluoroaldehydes **4** by treatment of an aldehyde **1** with NFSI (*N*-fluorobenzenesulfonamide) **2** and catalytic chiral imidazolidinone ligand **3** (Scheme 1).

Craig.lindsley@vanderbilt.edu.

Supporting Information Available: Experimental procedures, characterization data, chiral LC traces and ¹H, ¹⁹F and ¹³C NMR spectra for all new compounds, **7a–f**, **15a–i** and **18a–d**.

If these chiral α -fluoroaldehydes **4** were subjected to a reductive amination protocol, we surmised that chiral β -fluoroamines would result, and depending on the chirality of the imidazolidinone ligand, either the (*S*)- or (*R*)- β -fluoroamine would be delivered. Moreover, there are thousands of commercially available amines and aldehydes to employ as reactants, providing improved generality in terms of substrate scope. Surprisingly, this powerful extension of the MacMillan enantioselective α -fluorination of aldehydes has never been described.

We first explored the effect of NFSI equivalents, solvent and temperature on a prototypical α -fluorination reaction and subsequent reductive amination sequence employing organocatalyst **3** with phenylpropanal **5** and Bocpiperazine **6** to produce chiral β -fluoroamine **7** (Table 1). Our initial attempt (entry 1) employed the conditions prescribed by MacMillan¹¹ for the α -fluorination, with a quick aqueous work-up prior to the reductive amination step. Conversion and enantioselectivity to the desired β -fluoroamine were excellent, but about 20% of the undesired β,β -difluoroamine was observed. To avoid this side product, we decreased the equivalents for NFSI from 5.0 to 3.0 (entry 2), to 2.0 (entry 3) and finally 1.5 (entry 4). Only in the latter case, was the β,β -difluoroamine side product eliminated; moreover, the success of the α -fluorination was not hindered by decreasing the equivalents of costly NFSI and work-up was greatly improved. Other solvent systems were evaluated, with acetone (entry 6) proving to be generally useful, while CH_2Cl_2 (entry 7) suffered diminished yields (37%) and low ee (84%). Ultimately, optimal conditions for the two step sequence (entry 10) employed 1.0 equivalent of NFSI in THF at -20°C for 24 hours, followed by a quick aqueous work-up, suspension of the resulting α -fluoroaldehyde in $\text{ClCH}_2\text{CH}_2\text{Cl}$ with **6** and $\text{NaB}(\text{OAc})_3\text{H}$ at ambient temperature to provide enantiopure (>99% ee) **7** with 96% conversion and 80% isolated yield.

As shown in Tables 2 and 3, this two-pot protocol is general with respect to the amine component providing yields from 65–82% employing both primary and secondary amines, which include therapeutically relevant GPCR privileged structures.¹² Importantly, the (*S*)-imidazolidinone catalyst **3** provides the corresponding (*S*)- β -fluoroamines **7a–f** in 95–>99% ee (Table 2), while the (*R*)-imidazolidinone catalyst **3** provides the corresponding (*R*)- β -fluoroamines **8a–e** in 87–>95% ee (Table 3).

At this point, we wanted to explore the scope of this new methodology to produce β -fluoroamines employing alternative aldehydes and to determine if this new strategy would allow access to tertiary β -fluoroamines – a moiety inaccessible through DAST and other known chemistries.^{8–10} We envisioned that these transformations might require alternative organocatalysts to (*S*)- and (*R*)-**3**, so we assembled a catalyst screening kit comprised of **9–13** for evaluation (Figure 1).

As shown in Table 4, the methodology appears general with respect to both aldehyde and amine component, affording chiral β -fluoroamines in good isolated yields (58–92%) and with high enantioselectivities (>96% ee). If the aldehyde bears a β -stereogenic center, as in **15f**, the β -fluoroamine is still installed with high ee (>95%), but with a 1.2:1 dr. Compounds **15h** and **15i** represent transformations that all known standard β -fluoroamine methodology can not produce – tertiary β -fluoroamines.^{8–10} Standard conditions with (*S*)-**3** provide excellent chemical yield for installation of the tertiary β -fluoroamine, but suffers from low enantioselectivity (15% ee). Catalysts **9**, **10** and **13** provided poor conversion (<25%) and low %ee. Like (*S*)-**3**, catalysts **11** and **12** installed the tertiary β -fluoroamine in good chemical yields, but the maximum ee observed was 31% with catalyst **11**. A similar trend was observed in the synthesis of tertiary β -fluoroamine **15i**. Our standard methodology with (*S*)-**3** provided good conversion, but only 17% ee. Switching to the tetrazole catalyst **11** provided the desired tertiary β -fluoroamine **15i** in comparable yield, but with improved ee

(40%). Thus, our new methodology allows access to tertiary β -fluoroamines, and with modest % ee, as opposed to existing methods which are unable to install tertiary β -fluoroamines.

Our attention now turned to developing a one-pot organocatalytic approach to β -fluoroamines to avoid the aqueous work-up step. As shown in Table 5, this was smoothly accomplished by application of 1.0 equivalent of NFSI, at $-20\text{ }^{\circ}\text{C}$ for 3 hours in 10% *i*-PrOH/THF, followed by direct addition of 1.0 equivalent of mono-Boc-piperazine **6** and 2.2 equivalents of NaB(OAc)₃H for 16 hours. The desired β -fluoroamine **7** was delivered in 65% isolated yield and with >96% ee. The Boc protecting groups remained in tact, highlighting the mild conditions of this one-pot procedure.

Finally, there are many examples in the literature where a β,β -difluoroamine is required to address a specific liability of a candidate molecule.^{1–6} Based on an earlier observation of β,β -difluoroamine formation (Table 1) when excess NFSI was employed, we quickly developed a two-pot route to rapidly access this valuable moiety. In this instance (Table 6), aldehydes **16** were treated with two equivalents of NFSI, 40 mol% DL-proline in 10% *i*-PrOH/THF at room temperature for 24 hours to provide α,α -difluoroaldehydes **17**. After a quick aqueous work-up, the resulting oils were resuspended in DCE, amine and NaB(OAc)₃H were added, and the reaction was allowed to stir at room temperature for 16 hours to provide β,β -difluoroamines **18** in isolated yields ranging from 64–77%.

In summary, we have developed a powerful extension of the MacMillan enantioselective α -fluorination of aldehydes for the *general* enantioselective synthesis of β -fluoroamines in yields and % ee far exceeding that of any other reported method, and without rearranged and dehydrated side products. Moreover, our new methodology allows for the first synthesis of tertiary β -fluoroamines with enantioselectivities up to 40%. Furthermore, slight modification of our protocol provides rapid, high yielding access to β,β -difluoroamines. Overall, these novel strategies for the synthesis of β -fluoroamines and β,β -difluoroamines, from readily available precursors, represents a significant improvement in the art to access these therapeutically relevant moieties.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported, in part, by the Department of Pharmacology and Vanderbilt University. Funding for the NMR instrumentation was provided in part by a grant from NIH (S10 RR019022).

References

1. Hagmann WK. J. Med. Chem. 2008; 51:4359–4369. [PubMed: 18570365]
2. Muller K, Mainfisch P, Altmann KH, Schlosser M. ChemBioChem. 2004; 5:559–572.
3. Bohm H-J, Banner D, Bendels S, Kansy M, Kuhn B, Muller K, Obst-Sander U, Stahl M. ChemBioChem. 2004; 5:637–643. [PubMed: 15122635]
4. Kirk KL. Curr. Top. Med. Chem. 2006; 6:1445–1543.
5. Kirk KL. Curr. Top. Med. Chem. 2006; 6:1013–1029.
6. Morgenthaler M, Schweizer E, Hoffman-Roder F, Benini F, Martin RE, Jaeschke G, Wagner B, Fischer H, Bendels S, Zimmerli D, Schneider J, Hiedrich F, Kansy M, Muller K. ChemMedChem. 2007; 2:1100–1115. [PubMed: 17530727]
7. Percy JM. Sci. Synth. 2005; 34:379–416.
8. Alvenrhe GM, Lacombe S, Laurent AJ. Tetrahedron Lett. 1980; 21:289–293.

9. Thiabadeau S, Martin-Mingot A, Jouannetaud M-P, Karam O, Zunino F. Chem. Commun. 2007:3198–3200.
10. Hsin L-W, Chang L-T, Rothman RB, Dersch CM, Jacobson AE, Rice KC. J. Med. Chem. 2008; 51:2795–2806. [PubMed: 18393401]
11. Beeson TD, MacMillan DWC. J. Am.Chem. Soc. 2005; 127:8826–8828. [PubMed: 15954790]
12. Patchett AA, Nargund R. Ann. Reports Med. Chem. 2000; 35:289–298.

Figure 1.
Organocatalysts examined in determining scope of β -fluoroamine synthesis.

Scheme 1.
Organocatalytic α -fluorination of aldehydes

Table 1

Optimization of organocatalytic α -fluorination/ reductive amination sequence.

entry ^a	2 (equiv)	solvent	temp (°C)	time (h)	convn (%) ^d	ee (%) ^b
1 ^c	5.0	THF	-20	24	99	>98
2 ^c	3.0	THF	-20	24	98	>98
3 ^c	2.0	THF	-20	24	99	>99
4	1.5	THF	24	3	97	>98
5	1.5	THF	4	12	98	>98
6	1.5	acetone	24	3	91	>96
7	1.5	CH ₂ Cl ₂	24	3	37	84
8	1.5	EtOAc	24	3	89	95
9	1.2	THF	-20	24	99	>99
10	1.0	THF	-20	24	96	>99

^a All reactions were performed on a 0.05 mmol scale.

^b Enantiomeric excess were determined using chiral stationary phase HPLC

^c α,α -difluoro product was observed.

^d Conversion determined by LC/MS and ¹H NMR.

See Supporting Information for complete details.

Table 2

Scope of HNR_1R_2 in enantioselective synthesis of (*S*)- β -fluoroamines.

$\text{5} \xrightarrow[2. \text{HNR}_1\text{R}_2, \text{NaBH(OAc)}_3, \text{DCE, rt}]{1. \text{NFSI, 20 mol \% S-3, THF}/i\text{-PrOH, } -20^\circ\text{C}}$
 7 a-f

compd ^a	product	yield (%) ^b	ee (%) ^c
7a		80	>99 (S)
7b		70	>98 (S)
7c		76	>99 (S)
7d		69	>98 (S)
7e		65	>96 (S)
7f		82	>95 (S)

^a All reactions were performed on a 0.5 mmol scale and proceeded to complete conversion.

^b Yield after chromatography.

^c Enantiomeric excess were determined using chiral stationary phase

Table 3

Scope of HNR₁R₂ in enantioselective synthesis of (*R*)-β-fluoroamines.

5

1. NFSI, 20 mol % *R*-3
THF/-i-PrOH, -20 °C
2. HNR₁R₂, NaBH(OAc)₃
DCE, rt

8a-e

compd ^a	product	yield (%) ^b	ee (%) ^c
8a		70	>98 (R)
8b		80	>87 (R)
8c		76	>98 (R)
8d		69	>94 (R)
8e		65	>96 (R)

^a All reactions were performed on a 0.05 mmol scale and proceeded to complete conversion.

^b Yield after chromatography.

^c Enantiomeric excess were determined using chiral stationary phase HPLC.

See Supporting Information for more details.

Table 4

Scope of β -fluoroamine synthesis via organocatalysis.

$ \begin{array}{c} \text{R}_1 \\ \\ \text{R}_2 - \text{CH} - \text{CHO} \\ \\ \text{14} \end{array} \xrightarrow[2. \text{HNR}_3\text{R}_4, \text{NaBH}(\text{OAc})_3, \text{DCE, rt}]{1. \text{NFSI, 20 mol \% cat.}, \text{THF}/i\text{-PrOH, } -20^\circ\text{C}} \begin{array}{c} \text{R}_1 \\ \\ \text{R}_2 - \text{CH} - \text{CH}_2 - \text{NR}_3\text{R}_4 \\ \\ \text{F} \\ \text{15a-i} \end{array} $				
compd ^a	product	cat.	yield (%) ^b	ee (%) ^c
15a		(S)-3	87	>99
15b		(S)-3	92	>98
15c		(S)-3	90	>96
15d		(S)-3	84	>99
15e		(S)-3	88	>99
15f		(S)-3	75	>95 1.2:1 dr ^e
15g		(S)-3	58	nd ^d

compd ^a	product	cat.	yield (%) ^b	ee (%) ^c
15h		(S)- 3	93	15
		9	25	13
		10	<10	nd ^d
		11	94	31
		12	83	16
		13	16	12
15i		(S)- 3	74	17
		11	75	40

^a All reactions were performed on a 0.05 mmol scale and proceeded to complete conversion.

^b Yield after chromatography.

^c Enantiomeric excess were determined using chiral stationary phase HPLC.

^d Not determined.

^e Diastereomer ratios were measured by ¹⁹F NMR.

See Supporting Information for complete details.

Table 5

One-pot β -fluoroamine synthesis via organocatalysis

entry ^a	solvent	temp (°C)	time (h)	yield (%) ^c	ee (%) ^b
1	THF	24	3	45	>95
2	CH ₃ CN	24	3	36	>95
3	CH ₂ Cl ₂	24	24	12	nd ^d
4	DCE	24	24	0	nd ^d
5	THF/ <i>i</i> -PrOH	-20	3	65	>96

^a All reactions were performed on a 0.05 mmol scale.

^b Enantiomeric excess were determined using chiral stationary phase HPLC.

^c Yield after chromatography.

^d Not determined.

Table 6

β,β -difluoroamine synthesis via organocatalysis

cmpd ^a	product	yield (%) ^b
18a		64
18b		67
18c		77
18d		68

^a All reactions were performed on a 0.05 mmol scale and proceeded to complete conversion.

^b Yield after chromatography